Literature DB >> 31584385

Serum Albumin as a Biomarker of Pulmonary Sarcoidosis Chronicity.

Safayeth Jabeen Isma1, Hesham R Omar2, Nadera Sweiss3, Mehdi Mirsaeidi1.   

Abstract

OBJECTIVES: The duration of sarcoidosis is associated with a higher risk of irreversible pulmonary fibrosis. Sarcoidosis shows diverse clinical presentations, which may lead to a delayed diagnosis due to lack of a specific diagnostic test. Biomarkers of sarcoidosis duration have not been previously explored.
MATERIALS AND METHODS: A retrospective study was conducted to investigate independent biomarkers of pulmonary sarcoidosis duration.
RESULTS: A total of 108 cases with pulmonary sarcoidosis (mean age 53.4 years; 76.9% females; average duration of sarcoidosis 12 years) were included in the study. We found significant correlation between the duration of sarcoidosis and serum albumin levels (r=-0.414, p=0.0001), sedimentation rate (r=0.375, p=0.001), pulmonary artery systolic pressure (r= 0.468, p=0.003), diffusion capacity (r=-0.334, p=0.002), and age (r=0.492, p=0.0001). A multivariate linear regression analysis revealed that serum albumin levels (β=-5.242, 95% confidence interval [CI] -8.372 to -2.112, p=0.001) and age (β=0.367, 95% CI 0.164 to 0.570, p=0.001) were independent correlates of sarcoidosis duration. A receiver operating characteristics curve analysis for prediction of sarcoidosis of a >10 years duration gave an area under curve (AUC) of 0.722 (95% CI 0.620-0.824, p<0.0001) for serum albumin and an AUC of 0.665 (95% CI 0.561-0.768, p<0.004) for age. An albumin level <2.4 gm/dL yielded a 90.5% sensitivity and 98.2% specificity for predicting sarcoidosis of >10 years duration. In comparison, the patient age of 51.5 years yielded a 70.2% sensitivity and 50% specificity for predicting patients with sarcoidosis for >10 years.
CONCLUSION: The serum albumin level may be a biomarker of pulmonary sarcoidosis duration and chronicity of disease. Further investigations are required to confirm its predictive ability.

Entities:  

Year:  2019        PMID: 31584385      PMCID: PMC6777660          DOI: 10.5152/TurkThoracJ.2018.094

Source DB:  PubMed          Journal:  Turk Thorac J        ISSN: 2148-7197


  14 in total

Review 1.  The meaning of hypoalbuminaemia in clinical practice.

Authors:  G Franch-Arcas
Journal:  Clin Nutr       Date:  2001-06       Impact factor: 7.324

Review 2.  Sarcoidosis: clinical update.

Authors:  U Costabel
Journal:  Eur Respir J Suppl       Date:  2001-09

Review 3.  Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization.

Authors:  B A Rybicki; M Major; J Popovich; M J Maliarik; M C Iannuzzi
Journal:  Am J Epidemiol       Date:  1997-02-01       Impact factor: 4.897

Review 4.  Sarcoidosis.

Authors:  L S Newman; C S Rose; L A Maier
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

5.  Serum albumin levels correlate with inflammation rather than nutrition supply in burns patients: a retrospective study.

Authors:  Soshi Ishida; Ichiro Hashimoto; Takuya Seike; Yoshiro Abe; Yutaka Nakaya; Hideki Nakanishi
Journal:  J Med Invest       Date:  2014

6.  Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients.

Authors:  E Neville; A N Walker; D G James
Journal:  Q J Med       Date:  1983

Review 7.  Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

8.  Osseous disease in patients with pulmonary sarcoidosis and musculoskeletal symptoms.

Authors:  A F Shorr; F T Murphy; W R Gilliland; W Hnatiuk
Journal:  Respir Med       Date:  2000-03       Impact factor: 3.415

9.  Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis.

Authors:  Snjezana Rothkrantz-Kos; Marja P van Dieijen-Visser; Paul G H Mulder; Marjolein Drent
Journal:  Clin Chem       Date:  2003-09       Impact factor: 8.327

Review 10.  Sarcoidosis.

Authors:  Jennifer J Wu; Karin Rashcovsky Schiff
Journal:  Am Fam Physician       Date:  2004-07-15       Impact factor: 3.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.